Although proteomic profiling offers valuable insights, a comprehensive understanding of IDH1-mutant gliomas to aid treatment decisions will require integrative multi-omics approaches, including DNA/RNA methylation profiling, histone and protein post-translational modifications, and targeted DNA damage and repair assays. This evidence concerns the gene IDH1 and central nervous system cancer.